The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 354:2616-2617 June 15, 2006 Number 24
NextNext

ACAT Inhibition and the Progression of Coronary Atherosclerosis

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Nissen, S. E.
-PubMed Citation
To the Editor: Nissen et al. (March 23 issue)1 report on the ACAT Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) study, in which patients with coronary disease were treated with an enzyme acyl–coenzyme A:cholesterol acyltransferase (ACAT) inhibitor, pactimibe, to evaluate the potential for beneficial effects on coronary-artery atherosclerosis. We believe the authors' sweeping conclusion that ACAT inhibition is not an effective strategy for limiting atherosclerosis and that such treatment may promote atherogenesis is premature.

As the article pointed out, there are two types of ACATs (ACAT1 and ACAT2), which have distinct physiologic roles. Studies in animals show that the inhibition of ACAT1 . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.